Corcept Therapeutics: Q2 Gains Overshadowed By Generic Competition And Speculative Pipeline

Corcept Therapeutics Overview For some background: The conflict between Corcept and Teva revolves around Corcept's Cushing's drug, Korlym, which was first approved in 2012. After the drug enjoyed several years of orphan drug exclusivity, Teva filed an ANDA in 2018 for a generic version, prompting a legal dispute. The dispute is regarding a couple of Corcept's key patents, particularly U.S. Patents 10,195,214 and 10,842,800, that cover methods of safely administering Korlym with CYP3A4 inhibitors. In late De ...